Trial Outcomes & Findings for PVSRIPO for Recurrent Glioblastoma (GBM) (NCT NCT01491893)
NCT ID: NCT01491893
Last Updated: 2023-09-28
Results Overview
The MTD will be the highest dose level for which the probability that a dose escalation patient experiences a dose-limiting toxicity (DLT) is estimated to be less than 20%. Any Grade 3 or 4 toxicity that is not reversible within 2 weeks, or any life-threatening event, or treatment-related death will be considered a DLT. Any grade 2 or higher serious autoimmune toxicities particularly those affecting vital organs (e.g. cardiac, renal, CNS) will be considered a DLT. 50% Tissue Culture Infective Dose (TCID50) is the unit of measure of infectious virus titer. The MTD was determined based on the first 9 patients treated with PVSRIPO- 1 at dose level 1 (1.0 x 10e8 TCID50 (50% Tissue Culture Infectious Dose)), 1 at dose level 2 (3.3 x 10e8 TCID50), 1 at dose level 3 (1.0 x 10e9 TCID50), 2 at dose level 4 (3.3 x 10e9 TCID50), and 4 at dose level 5 (1.0 x 10e10 TCID50).
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
61 participants
Primary outcome timeframe
28 days after administration of PVSRIPO
Results posted on
2023-09-28
Participant Flow
Participant milestones
| Measure |
Dose Level 1 (Dose Escalation)
Participants received a single intratumoral infusion of 1.0 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 2 (Dose Escalation)
Participants received a single intratumoral infusion of 3.3 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 3 (Dose Escalation)
Participants received a single intratumoral infusion of 1.0 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 4 (Dose Escalation)
Participants received a single intratumoral infusion of 3.3 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 5 (Dose Escalation)
Participants received a single intratumoral infusion of 1.0 x 10\^10 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 4 (Dose De-escalation)
Participants received a single intratumoral infusion of 3.3 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 2 (Dose Expansion)
Participants received a single intratumoral infusion of 3.3 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level -1 (Dose Expansion)
Participants received a single intratumoral infusion of 5.0 x 10\^7 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level -2 (Dose Expansion)
Participants received a single intratumoral infusion of 1.0 x 10\^7 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level -1 (Selected Dose Expansion)
Participants received a single intratumoral infusion of 5.0 x 10\^7 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
1
|
1
|
1
|
1
|
4
|
1
|
6
|
24
|
15
|
7
|
|
Overall Study
COMPLETED
|
1
|
1
|
1
|
1
|
4
|
1
|
6
|
24
|
15
|
7
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
PVSRIPO for Recurrent Glioblastoma (GBM)
Baseline characteristics by cohort
| Measure |
Recombinant Nonpathogenic Polio-Rhinovirus Chimera (PVSRIPO)
n=61 Participants
All participants who received a dose of PVSRIPO at any dose level
|
|---|---|
|
Age, Continuous
|
52.9 years
STANDARD_DEVIATION 12.3 • n=93 Participants
|
|
Sex: Female, Male
Female
|
25 Participants
n=93 Participants
|
|
Sex: Female, Male
Male
|
36 Participants
n=93 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=93 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
57 Participants
n=93 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=93 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=93 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=93 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=93 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=93 Participants
|
|
Race (NIH/OMB)
White
|
57 Participants
n=93 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=93 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=93 Participants
|
|
Region of Enrollment
United States
|
61 Participants
n=93 Participants
|
PRIMARY outcome
Timeframe: 28 days after administration of PVSRIPOPopulation: All participants who received a dose of PVSRIPO at any dose level
The MTD will be the highest dose level for which the probability that a dose escalation patient experiences a dose-limiting toxicity (DLT) is estimated to be less than 20%. Any Grade 3 or 4 toxicity that is not reversible within 2 weeks, or any life-threatening event, or treatment-related death will be considered a DLT. Any grade 2 or higher serious autoimmune toxicities particularly those affecting vital organs (e.g. cardiac, renal, CNS) will be considered a DLT. 50% Tissue Culture Infective Dose (TCID50) is the unit of measure of infectious virus titer. The MTD was determined based on the first 9 patients treated with PVSRIPO- 1 at dose level 1 (1.0 x 10e8 TCID50 (50% Tissue Culture Infectious Dose)), 1 at dose level 2 (3.3 x 10e8 TCID50), 1 at dose level 3 (1.0 x 10e9 TCID50), 2 at dose level 4 (3.3 x 10e9 TCID50), and 4 at dose level 5 (1.0 x 10e10 TCID50).
Outcome measures
| Measure |
Dose Escalation Patients
n=9 Participants
Dose Escalation Patients
|
Dose Level 2 (Dose Escalation)
Participants received a single intratumoral infusion of 3.3 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 3 (Dose Escalation)
Participants received a single intratumoral infusion of 1.0 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 4 (Dose Escalation)
Participants received a single intratumoral infusion of 3.3 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 5 (Dose Escalation)
Participants received a single intratumoral infusion of 1.0 x 10\^10 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
|---|---|---|---|---|---|
|
Maximum Tolerated Dose (MTD)
|
10,000,000,000 50% Tissue Culture Infectious Dose
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: 28 days after administration of PVSRIPOThe number of dose escalation patients experiencing a dose-limiting toxicity (DLT) will be reported. Any grade 3 or any Grade 4 toxicity that is not reversible within 2 weeks, or any life-threatening event, or treatment-related death will be considered a DLT. Any grade 2 or higher serious autoimmune toxicities particularly those affecting vital organs (e.g. cardiac, renal, CNS) will also be considered a DLT.
Outcome measures
| Measure |
Dose Escalation Patients
n=1 Participants
Dose Escalation Patients
|
Dose Level 2 (Dose Escalation)
n=1 Participants
Participants received a single intratumoral infusion of 3.3 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 3 (Dose Escalation)
n=1 Participants
Participants received a single intratumoral infusion of 1.0 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 4 (Dose Escalation)
n=2 Participants
Participants received a single intratumoral infusion of 3.3 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 5 (Dose Escalation)
n=4 Participants
Participants received a single intratumoral infusion of 1.0 x 10\^10 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
|---|---|---|---|---|---|
|
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: 5 yearsThe RP2D of PVSRIPO is the safe, therapeutic dose where patients have not experienced undue side effects from PVSRIPO or from the management of cerebral inflammation secondary to PVSRIPO administration. 50% Tissue Culture Infective Dose (TCID50) is the unit of measure of infectious virus titer.
Outcome measures
| Measure |
Dose Escalation Patients
n=61 Participants
Dose Escalation Patients
|
Dose Level 2 (Dose Escalation)
Participants received a single intratumoral infusion of 3.3 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 3 (Dose Escalation)
Participants received a single intratumoral infusion of 1.0 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 4 (Dose Escalation)
Participants received a single intratumoral infusion of 3.3 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 5 (Dose Escalation)
Participants received a single intratumoral infusion of 1.0 x 10\^10 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
|---|---|---|---|---|---|
|
Recommended Phase 2 Dose (RP2D)
|
50000000 50% Tissue Culture Infectious Dose
|
—
|
—
|
—
|
—
|
Adverse Events
Dose Level 1 Patients
Serious events: 1 serious events
Other events: 1 other events
Deaths: 0 deaths
Dose Level 2 Patients
Serious events: 3 serious events
Other events: 7 other events
Deaths: 6 deaths
Dose Level 3 Patients
Serious events: 1 serious events
Other events: 1 other events
Deaths: 1 deaths
Dose Level 4 Patients
Serious events: 1 serious events
Other events: 2 other events
Deaths: 2 deaths
Dose Level 5 Patients
Serious events: 3 serious events
Other events: 4 other events
Deaths: 4 deaths
Dose Level -1 Patients
Serious events: 7 serious events
Other events: 31 other events
Deaths: 24 deaths
Dose Level -2 Patients
Serious events: 5 serious events
Other events: 15 other events
Deaths: 12 deaths
Serious adverse events
| Measure |
Dose Level 1 Patients
n=1 participants at risk
Participants received a single intratumoral infusion of 1.0 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 2 Patients
n=7 participants at risk
Participants received a single intratumoral infusion of 3.3 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 3 Patients
n=1 participants at risk
Participants received a single intratumoral infusion of 1.0 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 4 Patients
n=2 participants at risk
Participants received a single intratumoral infusion of 3.3 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 5 Patients
n=4 participants at risk
Participants received a single intratumoral infusion of 1.0 x 10\^10 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level -1 Patients
n=31 participants at risk
Participants received a single intratumoral infusion of 5.0 x 10\^7 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level -2 Patients
n=15 participants at risk
Participants received a single intratumoral infusion of 1.0 x 10\^7 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Cardiac arrhythmia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Eye disorders
Visual field cut - hemianopia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Diarrhea
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Pancreatic hemorrhage
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Death NOS
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Fatigue
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Fever
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Malaise
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Steroid myopathy
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Enterocolitis infectious
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Lung infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Skin infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Platelet count decreased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor pain
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Cognitive disturbance
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Dysphasia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Dystonia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Edema cerebral
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Headache
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Hydrocephalus
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Intracranial hemorrhage
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Pyramidal tract syndrome
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Seizure
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
12.9%
4/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Confusion
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Delusions
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Depression
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Suicidal ideation
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Vascular disorders
Thromboembolic event
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
Other adverse events
| Measure |
Dose Level 1 Patients
n=1 participants at risk
Participants received a single intratumoral infusion of 1.0 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 2 Patients
n=7 participants at risk
Participants received a single intratumoral infusion of 3.3 x 10\^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 3 Patients
n=1 participants at risk
Participants received a single intratumoral infusion of 1.0 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 4 Patients
n=2 participants at risk
Participants received a single intratumoral infusion of 3.3 x 10\^9 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level 5 Patients
n=4 participants at risk
Participants received a single intratumoral infusion of 1.0 x 10\^10 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level -1 Patients
n=31 participants at risk
Participants received a single intratumoral infusion of 5.0 x 10\^7 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
Dose Level -2 Patients
n=15 participants at risk
Participants received a single intratumoral infusion of 1.0 x 10\^7 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
|
|---|---|---|---|---|---|---|---|
|
General disorders
Chills
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Blood and lymphatic system disorders
Anemia
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
57.1%
4/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
2/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
75.0%
3/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
61.3%
19/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
73.3%
11/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Cardiac disorders
Cardiac arrhythmia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Ear and labyrinth disorders
Ear and labyrinth disorders
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Ear and labyrinth disorders
Hearing impaired
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Endocrine disorders
Cushingoid
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Endocrine disorders
Diabetes
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Eye disorders
Blurred vision
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Eye disorders
Diplopia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Eye disorders
Eye disorders - Other, specify
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Eye disorders
Farsighted
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Eye disorders
Focusing difficulty
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Eye disorders
Strabismus
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Eye disorders
Visual field cut - hemianopia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
29.0%
9/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
22.6%
7/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
26.7%
4/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Diarrhea
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.8%
8/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Fecal incontinence
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Gastrointestinal disorders - Other, specify
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Gingivitis
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Hemorrhoids
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Lower gastrointestinal hemorrhage
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Mucositis oral
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Nausea
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
42.9%
3/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
41.9%
13/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Taste disorder
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Gastrointestinal disorders
Vomiting
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
19.4%
6/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Edema face
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Fatigue
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
42.9%
3/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
2/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
2/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
35.5%
11/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Fever
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Gait disturbance
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
12.9%
4/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Infusion related reaction
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Irritability
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Pain
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
42.9%
3/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
45.2%
14/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
33.3%
5/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
General disorders
Steroid myopathy
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
2/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Immune system disorders
Allergic reaction
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Bronchial infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Conjunctivitis infective
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Infections and infestations - Other, specify
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Lung infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Mucosal infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Phlebitis infective
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Skin infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Upper respiratory infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
29.0%
9/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
40.0%
6/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Injury, poisoning and procedural complications
Bruising
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Injury, poisoning and procedural complications
Burn
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
12.9%
4/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Injury, poisoning and procedural complications
Vascular access complication
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
16.1%
5/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
26.7%
4/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Alkaline phosphatase increased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Aspartate aminotransferase increased
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
2/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
29.0%
9/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
26.7%
4/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Creatinine increased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
22.6%
7/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
2/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
41.9%
13/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
46.7%
7/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
16.1%
5/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
Platelet count decreased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
57.1%
4/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
2/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
29.0%
9/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
40.0%
6/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Investigations
White blood cell decreased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
22.6%
7/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Anorexia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
12.9%
4/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
85.7%
6/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
2/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
71.0%
22/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
33.3%
5/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hypermagnesemia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hypernatremia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
57.1%
4/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
75.0%
3/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
58.1%
18/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
53.3%
8/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
57.1%
4/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
2/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
41.9%
13/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
46.7%
7/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
22.6%
7/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
2/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
29.0%
9/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
40.0%
6/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
2/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
32.3%
10/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
19.4%
6/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Musculoskeletal and connective tissue disorders
Buttock pain
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Musculoskeletal and connective tissue disorders
Muscle cramp
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Cognitive disturbance
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
71.4%
5/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
22.6%
7/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Dysphasia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
2/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
41.9%
13/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Dystonia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Facial muscle weakness
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Headache
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
71.4%
5/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
2/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
74.2%
23/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
60.0%
9/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Intracranial hemorrhage
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Myokymia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Nervous system disorders - Other, specify
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Paresthesia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
42.9%
3/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.8%
8/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Pyramidal tract syndrome
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
75.0%
3/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
58.1%
18/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
53.3%
8/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Restless leg syndrome
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Seizure
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
85.7%
6/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
75.0%
3/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
48.4%
15/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
66.7%
10/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Nervous system disorders
Tremor
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Agitation
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
16.1%
5/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Confusion
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
28.6%
2/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
22.6%
7/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Depression
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Hallucinations
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
57.1%
4/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.8%
8/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Psychiatric disorders
Suicidal ideation
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Renal and urinary disorders
Hematuria
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
16.1%
5/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Renal and urinary disorders
Renal and urinary disorders - Other, specify
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Renal and urinary disorders
Renal calculi
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Renal and urinary disorders
Urinary frequency
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
12.9%
4/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Reproductive system and breast disorders
Irregular menstruation
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Reproductive system and breast disorders
Vaginal hemorrhage
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
12.9%
4/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
12.9%
4/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Hoarseness
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
50.0%
1/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
9.7%
3/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Postnasal drip
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
19.4%
6/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders - Other, specify
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnea
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
16.1%
5/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.8%
8/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, specify
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Skin and subcutaneous tissue disorders
Skin trauma
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
12.9%
4/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
13.3%
2/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Social circumstances
Menopause
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
3.2%
1/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Surgical and medical procedures
Surgical and medical procedures - Other, specify
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Vascular disorders
Hot flashes
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.5%
2/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Vascular disorders
Hypertension
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
14.3%
1/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.8%
8/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
20.0%
3/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
|
Vascular disorders
Thromboembolic event
|
0.00%
0/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/7 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
100.0%
1/1 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/2 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
25.0%
1/4 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
0.00%
0/31 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
6.7%
1/15 • From PVSRIPO administration until a patient is taken off study for disease progression or the participant started a new treatment regimen (average of 10 months).
This includes all adverse events regardless of attribution to study treatment from the time of PVSRIPO administration until the patient is taken off study or is retreated with PVSRIPO. For the reporting of adverse events per dose level, all patients receiving a specific dose were combined.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place